Otulana acquired 25,000 shares at a price of 38.8 US cents each, and now holds 50,000 shares.
Allergy Therapeutics closed up 0.7% to
Fri, 16th Mar 2018 17:30
Otulana acquired 25,000 shares at a price of 38.8 US cents each, and now holds 50,000 shares.
Allergy Therapeutics closed up 0.7% to
IN BRIEF: Allergy Therapeutics Kicks Off Grass Allergy Therapy Study
Read more(Sharecast News) - Commercial biotechnology company Allergy Therapeutics announced the screening of the first patient in its exploratory field study 'G309', to evaluate the efficacy and safety of 'Grass MATA MPL' in subjects with seasonal allergic rhinitis or rhinoconjunctivitis induced by grass pollen exposure.
Read moreUK EARNINGS SUMMARY: LoopUp Swings To Profit On Work-From-Home Boost
Read moreIN BRIEF: Allergy Therapeutics Secures VLP Technology Platform
Read more(Sharecast News) - Biotechnology company Allergy Therapeutics announced further investment in virus-like particle (VLP) technology for applications beyond the allergy immunotherapy field on Thursday.
Read moreUK TRADING UPDATE SUMMARY: Finsbury Food's Annual Revenue Set To Fall
Read more(Sharecast News) - Biotechnology company Allergy Therapeutics reported a "strong" full-year performance on Wednesday despite challenges stemming from the Covid-19 pandemic.
Read moreIN BRIEF: Allergy Therapeutics To Recommence Birch B301 Trial
Read more(Sharecast News) - Biotechnology company Allergy Therapeutics announced the outcome of scientific advice from the German Regulatory Authority, the Paul Ehrlich Institute (PEI), over invalidation of the primary endpoint data of the Birch MATA MPL pivotal phase 3 clinical trial, or 'B301', on Thursday.
Read moreAllergy Therapeutics Anticipates Profit Ahead Of Expectations
Read more(Sharecast News) - Biotechnology company Allergy Therapeutics said on Wednesday that its 2020 trading performance was on track to exceed market expectations.
Read moreAllergy Therapeutics Well-Placed Despite Regulatory "Challenge"
Read moreUK Earnings, Trading Statements Calendar - Next 7 Days
Read moreAllergy Therapeutics Outlook Confident As Revenue Rises In First Half
Read more(Sharecast News) - Commercial biotechnology company Allergy Therapeutics updated the market on its grass MATA MPL phase 3 study, due to start in autumn 2020, on Tuesday, reporting that following further investigation of the phase 3 birch MATA MPL study, the upcoming grass study would now take a 'stepwise approach'.
Read more